Pharmacokinetic model for Remimazolam in patients undergoing cardiac surgery

Pharmacokinetic model for Remimazolam in patients undergoing cardiac surgery - Pharmacokinetic model for Remimazolam in patients undergoing cardiac surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050602

Enrollment

Registered

2023-03-16

Start date

2023-03-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aortic valve disease, angina

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients undergoing scheduled cardiac surgery under CPB

Exclusion criteria

Exclusion criteria: BMI >30 kg/m2, BMI <18 kg/m2, pregnant, myasthenia gravis, acute angle closure glaucoma, patients with severe hepatic dysfunction, emergency surgery

Design outcomes

Primary

Measure	Time frame
Remimazolam is administered to patients undergoing cardiac surgery and arterial blood draws are performed as appropriate. Blood draws should be performed only during surgery.	—

Countries

Japan

Contacts

Public ContactAmi Sugawara

Asahikawa Medical University Department of Anesthesiology and Critical Care Medicine

asugawara@asahikawa-med.ac.jp0166652111

Outcome results